Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tempus AI, Inc (TEM) Fair Value & Analysis

Healthcare · US · Market cap $8.6B

Price$48.61
Fair Value$12.67
Upside-73.9%
Quality95/100
Evidence: Low Range $9.50 – $15.84

Analysis

Tempus AI, Inc (TEM) currently trades at $48.61, while our model-based Fair Value estimate is $12.67 — implying the stock looks roughly 73.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inh…

Open the full interactive analysis →

Similar stocks

Veeva Systems Inc (VEEV) -35% Pro Medicus Limited (PME) -83% BrightSpring Health Services, Inc (BTSG) -68% HealthEquity, Inc (HQY) -33% M3, Inc (MTHRY) +2% Hinge Health, Inc (HNGE) -56%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.